1. Home
  2. WST vs EXAS Comparison

WST vs EXAS Comparison

Compare WST & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Pharmaceutical Services Inc.

WST

West Pharmaceutical Services Inc.

HOLD

Current Price

$249.11

Market Cap

18.7B

Sector

Health Care

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$102.36

Market Cap

19.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WST
EXAS
Founded
1923
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.7B
19.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WST
EXAS
Price
$249.11
$102.36
Analyst Decision
Buy
Buy
Analyst Count
7
19
Target Price
$338.00
$84.27
AVG Volume (30 Days)
744.1K
2.1M
Earning Date
02-12-2026
02-18-2026
Dividend Yield
0.34%
N/A
EPS Growth
0.17
N/A
EPS
6.75
N/A
Revenue
$3,017,900,000.00
$3,082,033,000.00
Revenue This Year
$6.97
$19.40
Revenue Next Year
$6.27
$13.51
P/E Ratio
$37.79
N/A
Revenue Growth
4.92
14.47
52 Week Low
$187.43
$38.81
52 Week High
$348.90
$102.66

Technical Indicators

Market Signals
Indicator
WST
EXAS
Relative Strength Index (RSI) 33.02 80.22
Support Level $244.70 $102.00
Resistance Level $281.55 $102.56
Average True Range (ATR) 10.24 0.33
MACD -3.19 -0.54
Stochastic Oscillator 8.19 72.49

Price Performance

Historical Comparison
WST
EXAS

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: